1h Free Analyst Time
The premature ejaculation disorder market in US is forecasted to grow by USD 478.41 mn during 2023-2028, accelerating at a CAGR of 10.22% during the forecast period. The report on the premature ejaculation disorder market in US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high efficacy of off-label drugs leading to high usage by people, demand for topical drug therapies to treat premature ejaculation, and growing risk factors causing premature ejaculation.
The premature ejaculation disorder market in US is segmented as below:
By Route Of Administration
- Oral
- Topical
By Drug Class
- SSRIs
- PDE5 inhibitors
- Amide anesthetics
- Others
By Distribution Channel
- Prescription
- OTC
The report on the premature ejaculation disorder market in US covers the following areas:
- Premature ejaculation disorder market in US sizing
- Premature ejaculation disorder market in US forecast
- Premature ejaculation disorder market in US industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Drug Class
8 Market Segmentation by Distribution Channel
9 Customer Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the premature ejaculation disorder market in US: Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Bayer AG, Cipla Ltd., Eli Lilly and Co., Johnson and Johnson, Lupin Ltd., NeuroHealing Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Prinston Pharmaceutical Inc., Teva Pharmaceutical Industries Ltd., Veru Inc., VIVUS LLC, Aytu BioPharma Inc., Royalty Pharma plc, and Sebela Pharmaceuticals Inc..Commenting on the report, an analyst from the publisher said: 'The latest trend gaining momentum in the market is use of nanotechnology in drug delivery.'
According to the report, one of the major drivers for this market is the high efficacy of off-label drugs leading to high usage by people.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Absorption Pharmaceuticals LLC
- Alembic Pharmaceuticals Ltd.
- Amneal Pharmaceuticals Inc.
- Bayer AG
- Cipla Ltd.
- Eli Lilly and Co.
- Johnson and Johnson
- Lupin Ltd.
- NeuroHealing Pharmaceuticals Inc.
- Novartis AG
- Pfizer Inc.
- Prinston Pharmaceutical Inc.
- Teva Pharmaceutical Industries Ltd.
- Veru Inc.
- VIVUS LLC
- Aytu BioPharma Inc.
- Royalty Pharma plc
- Sebela Pharmaceuticals Inc.